Halozyme Therapeutics, Inc.
HALO
$64.45
$0.150.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 137.01M | 137.01M | 93.25M | 76.82M | 85.39M |
| Total Depreciation and Amortization | 20.42M | 20.36M | 20.33M | 20.21M | 20.69M |
| Total Amortization of Deferred Charges | 1.84M | 1.84M | 1.84M | 1.83M | 1.83M |
| Total Other Non-Cash Items | -6.17M | 10.10M | 22.65M | 9.01M | 20.54M |
| Change in Net Operating Assets | 25.37M | -53.94M | -82.26M | 21.56M | -26.10M |
| Cash from Operations | 178.47M | 115.38M | 55.79M | 129.43M | 102.35M |
| Capital Expenditure | -3.05M | -1.52M | -2.58M | -3.55M | -2.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.53M | -165.97M | -39.46M | -79.14M | -5.70M |
| Cash from Investing | 29.48M | -167.48M | -42.04M | -82.68M | -8.29M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 3.59M | 18.56M | 9.48M | -- | 2.38M |
| Repurchase of Common Stock | -250.00M | -- | -- | -489.00K | -252.30M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -246.42M | 18.56M | 9.48M | -489.00K | -249.92M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -38.47M | -33.55M | 23.24M | 46.26M | -155.86M |
